These data demonstrate that MCC950 targeting NLRP3 is clinically safe and is a potential treatment strategy for the autoinflammatory syndrome, but the pathological mechanism of NLRP3 involvement in the CNS disease still needs to be confirmed by more clinical samples. This evidence concerns the gene NLRP3 and autoinflammatory syndrome.